Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) and Cresco Labs (OTCMKTS:CRLBF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
Institutional & Insider Ownership
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 0.1% of Cresco Labs shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for Cellectar Biosciences and Cresco Labs, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectar Biosciences | 1 | 0 | 3 | 1 | 2.80 |
| Cresco Labs | 0 | 1 | 0 | 1 | 3.00 |
Earnings & Valuation
This table compares Cellectar Biosciences and Cresco Labs”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectar Biosciences | N/A | N/A | -$21.79 million | ($6.66) | -0.36 |
| Cresco Labs | $655.85 million | 0.52 | -$135.41 million | ($0.39) | -1.75 |
Cellectar Biosciences has higher earnings, but lower revenue than Cresco Labs. Cresco Labs is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Cresco Labs has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
Profitability
This table compares Cellectar Biosciences and Cresco Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectar Biosciences | N/A | -349.24% | -153.18% |
| Cresco Labs | -20.90% | -17.98% | -4.29% |
Summary
Cellectar Biosciences beats Cresco Labs on 7 of the 13 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
About Cresco Labs
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
